Thalidomide in Sickle Cell Disease Patients

Evaluating the Impact of Thalidomide on Pain and Inflammation Reduction in Sickle Cell Disease Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180603039959N4

Enrollment

Registered

2024-10-17

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle cell anemia. Hb-SS disease with crisis

Interventions

Thirty-two sickle cell anemia patients will be selected based on the study’s inclusion criteria. Adult patients will take 100 mg of thalidomide and 80 mg of aspirin nightly. For children, the dose of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study should include patients with sickle cell anemia who experience pain attacks and have healthy liver and kidney function.

Exclusion criteria

Exclusion criteria: Patients with severe heart, liver, or kidney failure, pregnant mothers, those with a history of chemotherapy, diabetic patients with fever, and those with acute or chronic inflammatory infections will be excluded. Additionally, patients who have taken anti-inflammatories in the two months before the study will not be eligible.

Design outcomes

Primary

Measure	Time frame
Visual Analog Scale for Pain (VAS) score. Timepoint: Start of treatment, three months after treatment. Method of measurement: The Visual Analog Scale (VAS) is a simple and effective tool for measuring pain intensity. It consists of a 10 cm line, where the left end represents 'no pain' and the right end signifies 'the worst possible pain.' Patients will mark their pain level on this line, and the distance from the left side to the marked point, measured in centimeters, will provide a pain score out of 10.;IL-6. Timepoint: Start of treatment, three months after treatment. Method of measurement: ELISA method is used to measure IL-6.;TNF-a. Timepoint: Start of treatment, three months after treatment. Method of measurement: ELISA method is used to measure TNF-a.;CRP. Timepoint: Start of treatment, three months after treatment. Method of measurement: ELISA method is used to measure CRP.;Neutrophil to lymphocyte ratio (N/L Ratio). Timepoint: Start of treatment, three months after treatment. Method of measurement: The ratio of neutrophils to lymphocytes (N/L ratio) is obtained from the results of complete blood count (CBC).	—

Measure

Time frame

Visual Analog Scale for Pain (VAS) score. Timepoint: Start of treatment, three months after treatment. Method of measurement: The Visual Analog Scale (VAS) is a simple and effective tool for measuring pain intensity. It consists of a 10 cm line, where the left end represents 'no pain' and the right end signifies 'the worst possible pain.' Patients will mark their pain level on this line, and the distance from the left side to the marked point, measured in centimeters, will provide a pain score out of 10.;IL-6. Timepoint: Start of treatment, three months after treatment. Method of measurement: ELISA method is used to measure IL-6.;TNF-a. Timepoint: Start of treatment, three months after treatment. Method of measurement: ELISA method is used to measure TNF-a.;CRP. Timepoint: Start of treatment, three months after treatment. Method of measurement: ELISA method is used to measure CRP.;Neutrophil to lymphocyte ratio (N/L Ratio). Timepoint: Start of treatment, three months after treatment. Method of measurement: The ratio of neutrophils to lymphocytes (N/L ratio) is obtained from the results of complete blood count (CBC).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza khedri

Ahvaz University of Medical Sciences

reza.khedri.1996.ajums@gmail.com+98 916 996 5483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026